Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option
We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.
ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
PR: Heidelberg Pharma appoints Chief Financial Officer
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
Stifel European Healthcare Summit
ICML International Conference on Malignant Lymphoma
EHA2023 Hybrid Congress
BIO International Convention